MX2009008560A - Sondas para diagnostico por la imagen. - Google Patents

Sondas para diagnostico por la imagen.

Info

Publication number
MX2009008560A
MX2009008560A MX2009008560A MX2009008560A MX2009008560A MX 2009008560 A MX2009008560 A MX 2009008560A MX 2009008560 A MX2009008560 A MX 2009008560A MX 2009008560 A MX2009008560 A MX 2009008560A MX 2009008560 A MX2009008560 A MX 2009008560A
Authority
MX
Mexico
Prior art keywords
imaging probes
cathepsin
observation
cells
formula
Prior art date
Application number
MX2009008560A
Other languages
English (en)
Inventor
Karl-Ulrich Wendt
Maik Kindermann
Anja Globisch
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MX2009008560A publication Critical patent/MX2009008560A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a sondas moleculares de la fórmula (I): (Ver fórmula I) como se define en la presente memoria, que permiten la observación de la actividad catalítica de una catepsina seleccionada en ensayos in vitro, en células o en organismos multicelulares, un método para su preparación y el uso de las mismas.
MX2009008560A 2007-02-28 2008-02-08 Sondas para diagnostico por la imagen. MX2009008560A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07004121 2007-02-28
EP07291315 2007-10-30
PCT/EP2008/000963 WO2008104271A2 (en) 2007-02-28 2008-02-08 Imaging probes

Publications (1)

Publication Number Publication Date
MX2009008560A true MX2009008560A (es) 2009-08-18

Family

ID=39323713

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008560A MX2009008560A (es) 2007-02-28 2008-02-08 Sondas para diagnostico por la imagen.

Country Status (12)

Country Link
US (1) US8771644B2 (es)
EP (1) EP2117605B1 (es)
JP (1) JP2010519320A (es)
KR (1) KR20090115944A (es)
AU (1) AU2008221036B2 (es)
BR (1) BRPI0808046A2 (es)
CA (1) CA2678717A1 (es)
HK (1) HK1141243A1 (es)
IL (1) IL200566A0 (es)
MX (1) MX2009008560A (es)
MY (1) MY162041A (es)
WO (1) WO2008104271A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3335079B2 (ja) * 1996-07-01 2002-10-15 シャープ株式会社 Ａｇｃ回路
EP2262783A2 (en) * 2008-02-21 2010-12-22 Sanofi-Aventis Covalently binding imaging probes
US9155471B2 (en) 2009-05-27 2015-10-13 Lumicell, Inc'. Methods and systems for spatially identifying abnormal cells
US9314304B2 (en) 2010-12-08 2016-04-19 Lumicell, Inc. Methods and system for image guided cell ablation with microscopic resolution
US20140113322A1 (en) * 2012-10-22 2014-04-24 The Johns Hopkins University Supramolecular nanobeacon imaging agents as protease sensors
WO2014152797A2 (en) 2013-03-14 2014-09-25 Lumicell, Inc. Medical imaging device and methods of use
EP3601261A4 (en) * 2017-03-30 2021-07-14 The Board of Trustees of the Leland Stanford Junior University CONTRAST AGENTS ACTIVATED BY A PROTEASE FOR IN VIVO IMAGING
CN112574227A (zh) * 2020-12-15 2021-03-30 井冈山大学 一类具有螺内胺连接吗啉结构的pH探针及其合成方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627027A (en) 1986-04-18 1997-05-06 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
DE3700908A1 (de) * 1987-01-14 1988-07-28 Geiger Reinhard Aminoluciferine, verfahren zu deren herstellung und deren verwendung bei der bestimmung von enzymaktivitaeten
GB9024129D0 (en) * 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
US5268468A (en) 1991-12-05 1993-12-07 Hoechst-Roussel Pharmaceuticals Incorporated N-nitrosophenoxybenzenepropanamine and N-1-chloroethyl carbamate intermediates
US6288037B1 (en) * 1996-01-29 2001-09-11 Basf Aktiengesellschaft Substrates and inhibitors for cysteine protease ICH-1
US6083486A (en) 1998-05-14 2000-07-04 The General Hospital Corporation Intramolecularly-quenched near infrared fluorescent probes
GB9812596D0 (en) 1998-06-11 1998-08-12 Amersham Pharm Biotech Uk Ltd Energy transfer assay method
TW200404789A (en) * 1999-03-15 2004-04-01 Axys Pharm Inc Novel compounds and compositions as protease inhibitors
GB9911417D0 (en) * 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
CA2374369A1 (en) 1999-05-27 2000-12-07 Merck Frosst Canada & Co. Assays for caspase activity using green fluorescent proteins
AU2002232681A1 (en) * 2000-11-10 2002-05-21 The Regents Of The Univeristy Of California Activity-dependent cysteine protease profiling reagent
WO2002056670A2 (en) * 2001-01-05 2002-07-25 The General Hospital Corporation Activatable imaging probes
US7354735B2 (en) 2001-05-24 2008-04-08 Hong Kong University Of Science And Technology Nucleic acid encoding fluorescent protein constructs and methods for detecting apoptosis
WO2003029823A1 (en) * 2001-08-27 2003-04-10 Irm Llc Combinatorial protease substrate libraries
AU2003216139B2 (en) 2002-02-01 2008-08-14 Promega Corporation Bioluminescent protease assay
WO2004028449A2 (en) * 2002-09-24 2004-04-08 The General Hospital Corporation Azulene dimer-quenched, near-infrared fluorescent probes
JP2006522102A (ja) * 2003-03-10 2006-09-28 エムピーエイ・テクノロジーズ・インコーポレイテッド 光診断法および光線力学的療法の両方のためのターゲット剤
WO2004089395A2 (en) 2003-04-01 2004-10-21 Aventis Pharmaceuticals Inc. Use of an inhibitor of cathepsin-s or -b to treat or prevent chronic obstructive pulmonary disease
MXPA06004422A (es) * 2003-10-24 2006-07-03 Aventis Pharma Inc Nuevos derivados de ceto-oxadiazol como inhibidores de las catepsinas.
AU2004290874A1 (en) 2003-11-19 2005-06-02 Novartis Ag Use of cathepsin K inhibitors in severe bone loss diseases
NO20035683D0 (no) * 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av prostatakreft
AU2005210631A1 (en) * 2004-01-30 2005-08-18 Schering Aktiengesellschaft Silinane compounds as cysteine protease inhibitors
WO2005082876A1 (en) 2004-03-01 2005-09-09 Medivir Uk Ltd C-5 substituted furanone dipeptide cathepsin s inhibitors
US20060073529A1 (en) * 2004-08-13 2006-04-06 Contag Christopher H Luciferyl peptide substrate
GB0427380D0 (en) 2004-12-14 2005-01-19 Novartis Ag Organic compounds
EP1841730A4 (en) 2005-01-19 2010-10-27 Merck Frosst Canada Ltd CATHEPSIN K INHIBITORS AND ATHEROSCLEROSIS
EP1841419A4 (en) * 2005-01-19 2009-02-25 Merck Frosst Canada Ltd INHIBITORS OF CATHEPSIN K AND OBESITY
WO2006126570A1 (ja) 2005-05-24 2006-11-30 National University Corporation Saitama University 生体反応又は生体内状態変化の複数同時解析法
US8968700B2 (en) * 2005-08-11 2015-03-03 The Board Of Trustees Of The Leland Stanford Junior University Imaging of protease activity in live cells using activity based probes
EP1929308A1 (en) 2005-09-01 2008-06-11 Promega Corporation Cell-based luminogenic and nonluminogenic proteasome assays

Also Published As

Publication number Publication date
BRPI0808046A2 (pt) 2014-07-08
MY162041A (en) 2017-05-31
EP2117605A2 (en) 2009-11-18
WO2008104271A2 (en) 2008-09-04
AU2008221036A1 (en) 2008-09-04
IL200566A0 (en) 2010-05-17
US20100189658A1 (en) 2010-07-29
AU2008221036B2 (en) 2014-03-20
US8771644B2 (en) 2014-07-08
HK1141243A1 (en) 2010-11-05
WO2008104271A3 (en) 2008-11-06
EP2117605B1 (en) 2012-09-26
KR20090115944A (ko) 2009-11-10
JP2010519320A (ja) 2010-06-03
CA2678717A1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
MY148484A (en) Caspase imaging probes
MX2009008560A (es) Sondas para diagnostico por la imagen.
WO2009103432A3 (en) Covalently binding imaging probes
TW200635938A (en) Fluorosurfactants
HK1215249A1 (zh) 標記的前列腺特異性膜抗原 的抑制子、生物學評估及作為成像試劑的用途
CR20110470A (es) Proteínas de union a il-17
CR20120158A (es) Compuestos de diòxido de iminotiadiazina como inhibidores de bace, composiciones y su uso.
WO2010081001A3 (en) Recurrent gene fusions in cancer
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
WO2009012109A3 (en) Cyanine-containing compounds for cancer imaging and treatment
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
EA020330B3 (ru) Хиназолиновые соединения
WO2009120919A3 (en) Fenofibrate dosage forms
IL206748A (en) Molecular test for @cancer @ breast cancer @
WO2011034906A3 (en) Recurrent gene fusions in prostate cancer
WO2011106322A3 (en) Biomarkers for acute ischemic stroke
BRPI1014983A2 (pt) Cultura contínua para produção de 1,3-propanodiol usando alta concentração de glicerina
TR201903026T4 (tr) S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari.
UA102289C2 (ru) Гербициды, полученные из циклопентадиона
TN2009000063A1 (en) Compounds and methods for 18f labeled agents
EP2008573A4 (en) BIOLOGICAL TESTING SYSTEM
AR068952A1 (es) Procedimiento para la preparacion de medetomidina
AU2010202926B2 (en) Markers and methods relating to the assessment of Alzheimer's disease
BR112012010760A2 (pt) caldo de fermentação inseticida a partir de actinomicetos
PT1922415E (pt) Uso de rd9 e is6110 como ácidos nucleicos-alvo para o diagnóstico da tuberculose, e fornecimento de alvos is6110 e rd9 compatíveis com uma utilização multiplex

Legal Events

Date Code Title Description
FG Grant or registration